According to the Market Statsville Group (MSG), the Global Docetaxel Market was valued at USD 114.78 million in 2023 and is expected to grow from USD 125.91 million in 2024 to USD 252.46 million by 2033, by exhibiting a CAGR of 9.70% during the forecast period (2024-2033)
Docetaxel is the chemotherapy drug primarily used to treat several types of cancers including breast, non-small cell lung cancer (NSCLC), prostate, and gastric cancer. Docetaxel is a taxane drug class which functions by inhibiting cell division to prevent proliferation of malignant cells. Growing incidence of cancer all over the globe repeatedly fuels the demand for chemotherapy drugs, like docetaxel. The world's elderly population has a higher propensity to develop cancer, further driving the market size. An ongoing research area towards combining docetaxel with other drugs or therapies to significantly increase its efficacy and reduce side effects expands its usage. The area of novel formulations like liposomal docetaxel and new formulations further develops drug delivery, thus ensuring reduced adverse effects. The rise in the accessibility of healthcare in emerging markets fuels the docetaxel market.
Moreover, Other driving factors of the docetaxel market are the multiple ongoing clinical trials on new indications and combinations. A recent improvement is also being brought about in the area of formulation to ensure smooth delivery of the drug along with reduced side effects. One of the newer products exemplifying this is Lipodox. Research is currently being conducted in creating a combination of docetaxel with other chemotherapy drugs or targeted therapy to increase efficacy and perhaps control resistance. Increased healthcare access and cancer treatment availability in emerging markets affect the growth of the docetaxel market. The market is comprised of significant players-original developers, as well as generic manufacturers depth to the shifting scope of docetaxel treatment.
Definition of Docetaxel
It is also termed chemotherapy, which can be utilized to treat many types of cancer. As a medication, docetaxel is classified under a group of drugs called taxanes, which are extracted from the yew tree. Docetaxel inhibits the normal functioning of the microtubules of a cell during its division process, thus stopping the cancer cells from being divided and reproduced.
Request Sample Copy of this Report: https://www.marketstatsville.com/request-sample/docetaxel-market?utm_source=free&utm_medium=harsh
Scope of the Docetaxel Market
The study categorizes the docetaxel market based on cancer type, drug formulation, application, and distribution channel at the regional and global levels.
By Cancer Type Outlook (Sales, USD Million, 2019-2033)
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Stomach Cancer
- Other Cancers
By Drug Formulation Outlook (Sales, USD Million, 2019-2033)
- Branded Docetaxel
- Generic Docetaxel
- Novel Formulations
By Application Outlook (Sales, USD Million, 2019-2033)
- Breast Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Prostate Cancer
- Gastric Cancer
- Others
By Distribution Channel Outlook (Sales, USD Million, 2019-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region Outlook (Sales, USD Million, 2019-2033)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Poland
- Russia
- The Netherlands
- Norway
- Czech Republic
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Malaysia
- Thailand
- Singapore
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Northern Africa
- Rest of MEA
Direct Purchase Report: https://www.marketstatsville.com/buy-now/docetaxel-market?opt=3338&utm_source=free&utm_medium=harsh
Breast Cancer segment accounts for the largest market share by Cancer Type
Based on the cancer type, breast cancer is the most common cancer worldwide, with an estimated 2.3 million new cases reported in 2020 according to the International Agency for Research on Cancer (IARC). It accounts for nearly 12% of all new cancer cases globally. With upgraded knowledge, discovery techniques, and other lifestyle factors, the prevalence of breast cancer is also on the rise. There is evidence of a relationship with menstrual and reproductive factors. These include early menstruation at age 12 or less and late menopause after age 55. Another risk factor is hormone replacement therapy. Obesity, alcoholism, and a sedentary lifestyle are conditions that significantly boost the risk of a person to develop breast cancer.
Furthermore, Docetaxel is another term for a taxane chemotherapy agent that inhibits microtubules' disassembly during cell division. It interferes with how an ordinary cell will divide and die, killing cancer cells by interfering with cells' ability to continuously reproduce themselves quickly in breast cancer. It also is used as an adjuvant following surgery to prevent the recurrence of the cancer; one often uses chemotherapy. It is given together with such agents as doxorubicin and cyclophosphamide. For locally advanced cancers, docetaxel can be given neoadjuvant so that tumors have been reduced in size before surgical intervention to render them more accessible. Docetaxel alone or in combination with other therapies is administered to suppress the disease and enhance the quality of life in metastatic breast cancer.
North America accounted for the largest market share by Region.
Based on the region, North America is the leader in the global docetaxel market on regional levels. This is due to the prevalence of breast cancer and non-small cell lung cancer (NSCLC), advanced healthcare infrastructure, and huge research and development activities. The presence of major pharmaceutical companies and well-established healthcare systems further supports market growth. Continuous advancements in drug formulations and combination therapies contribute to market expansion. Research into novel formulations of docetaxel, such as liposomal versions, is gaining traction. The FDA’s regulatory framework facilitates the approval and availability of new docetaxel formulations and generics, influencing market dynamics. Although high-priced branded docetaxel and health care are a challenge to some access of patients, the generics make it easy.
Competitive Landscape: Docetaxel Market
Docetaxel Market is a huge competitor which is very competitive within the industry. It has utilized partnerships, product launches, acquisitions, agreements, and growth to enhance its position within the market. Most business sectors focus on increasing the level of operations around the world. It also cultivates long-lasting partnerships.
Major players in the docetaxel market are:
- Sanofi
- Pfizer
- Reddy’s Laboratories
- Novartis AG (Sandoz)
- Sun pharma
- Beijing Union Pharmaceutical Factory
- Accord Healthcare
- Alembic Pharmaceuticals
- Fresenius Kabi
- Getwell Oncology
- GLS Pharma
- Teva Pharmaceuticals USA
- Xiromed
- Cisen Pharmaceutical
- Alkem Labs
- Qilu Pharmaceutical
- Actavis
- Taj Pharmaceuticals
Request For Report TOC: https://www.marketstatsville.com/table-of-content/docetaxel-market
Recent Development
- In June 2024, The company is currently balancing both streams and through in-licensing opportunities and partnerships, it is strengthening its portfolio. Hyderabad-based Dr Reddy's Laboratories looks at inorganic growth in the medium term to boost its chronic portfolio, a fast-growing evergreen segment of the Indian pharma market, in a bid to enter the top 5 among domestic pharma companies.
- In May 2023, Pfizer Inc. will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. Abstracts include new data from pivotal trials supporting ongoing regulatory reviews for three potential therapies, if approved, and new clinical data for six early pipeline assets. In addition, Pfizer will highlight its ongoing scientific leadership in breast cancer with additional real-world evidence (RWE) for IBRANCE® (palbociclib) and initial first-in-human results for its novel CDK4- and CDK2-selective inhibitors, respectively, and novel epigenetic modulator KAT6 inhibitor.
Comments
Post a Comment